Bioequivalence Study in Healthy Thai Volunteers Duloxetine Hydrochloride Delayed Release Capsules 60 mg and Reference Product (Cymbalta) in Healthy Thai Volunteers under Fed Conditions
Conditions
Interventions
Each capsule contains 60 mg duloxetine,Each capsule contains 60 mg duloxetine as duloxetine hydrochrloride.
Experimental Drug,Active Comparator Drug
Generic duloxetine hydrochloride delayed release capsules 60 mg,Duloxetine 60 mg hard gastro-resistant capsule, Cymbalta
Sponsors
International Bio Service Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Thai male or female subjects between the ages of 18 to 55 years. 2. Body mass index between 18.5 to 30.0 kg/m2. 3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4. Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 5. Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1: - Postmenopausal for at least 1 year or - Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months. 6. Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2. 7. Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
Exclusion criteria
Exclusion criteria: 1. History of allergic reaction or hypersensitivity to duloxetine or to any of the excipients. 2. History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper/hypothyroidism, diabetes mellitus), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper/hypotension), psychiatric (e.g. anxiety disorder, depression, mania), neurologic (e.g. seizures), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness. 3. History of suicidal thoughts, behavior or suicide attempts in the past 30 days prior to screening or during enrollment in the study. 4. History or evidence of chronic pain such as chronic lower back pain, peripheral neuropathic pain, fibromyalgia or osteoarthritis. 5. History of febrile illness within 7 days prior to check-in in each period. 6. History or evidence of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency. 7. History of problems with swallowing tablet or capsule. 8. History of sensitivity to heparin or heparin-induced thrombocytopenia. 9. Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy. 10.History of diarrhea or vomiting within 24 hours prior to check-in in each period. 11.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine). 12.Investigation of vital signs shows pulse rate less than 60 or more than 100 beats per minute on screening day or on the day of admission. If abnormal pulse rate detects, the measurement should be repeated two more times after take a rest for at least 5 minutes each. The last measurement value should be used to determine the subjects eligibility. 13.Have sitting systolic blood pressure of less than 90 mmHg or more than 139 mmHg and diastolic blood pressure of less than 60 mmHg or more than 89 mmHg on screening day and check-in day. If abnormal blood pressure detects, the measurement should be repeated two more times after take a rest for at least 5 mins each. The last measurement value should be used to determine the subjects eligibility. 14.12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subjects eligibility. 15.Investigation with blood sample shows positive test for HBsAg. 16.Abnormal liver function, is greater than or equal to 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test. 17. Have eGFR (CKD-EPI) <30 mL/min/1.73 m2 based on serum creatinine results, at the screening laboratory test or during enrollment. 18.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study. 19.History or evidence of alcoholism or harmful use of alcohol within 2 years prior to screening i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax, AUC0-tlast and AUC0- infinity 0-48 hrs Mass spectrometry (LC-MS/MS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Tmax, t1/2, lambda z, AUC0-tlast/AUC0- infinity, AUC%extrapolate and MRT 0-48 hrs Mass spectrometry (LC-MS/MS) | — |
Countries
Thailand
Contacts
Public ContactThanaporn Wongyai
International Bio Service Co., Ltd.
Outcome results
None listed